Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).The Journal of antimicrobial chemotherapy · 2016
   Article
2. Analysis of single-nucleotide polymorphisms (SNPs) in human CYP3A4 and CYP3A5 genes: potential implications for the metabolism of HIV drugs.BMC medical genetics · 2014
   Article
3. CYP3A5 polymorphism, amlodipine and hypertension.Journal of human hypertension · 2014
   Review
4. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.Clinical pharmacokinetics · 2013
   Review
5. African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases.Evolution, medicine, and public health · 2013
   Article
6. PharmGKB summary: very important pharmacogene information for CYP3A5.Pharmacogenetics and genomics · 2012
   Article
7. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.The Journal of antimicrobial chemotherapy · 2009
   Article
8. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.AIDS (London, England) · 2008
   Article
9. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.Drug metabolism and disposition: the biological fate of chemicals · 2008
   Article
10. An examination of the effect of intestinal first pass extraction on intestinal lymphatic transport of saquinavir in the rat.Pharmaceutical research · 2008
    Article
11. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.British journal of clinical pharmacology · 2007
    Article
12. The impact of host pharmacogenetics on antiretroviral drug disposition.Current infectious disease reports · 2006
    Article
13. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.Current HIV/AIDS reports · 2006
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as